✦ LIBER ✦

Treatment of adult acute lymphoblastic leukemia with adriamycin, vincristine, and prednisone

✍ Scribed by Aviles, Agustin ;Sinco, Armando ;Rivera, Raul ;Ambriz, Raul ;Herrera, Jose G. ;Pizzuto, Javier

Publisher: John Wiley and Sons
Year: 1983
Tongue: English
Weight: 413 KB
Volume: 11
Category: Article
ISSN: 0098-1532
DOI: 10.1002/mpo.2950110214

No coin nor oath required. For personal study only.

✦ Synopsis

At the present time, it is possible to achieve up to a 95% complete remission in childhood acute lymphoblastic leukemia, using the combination of vincristine and prednisone.

Nevertheless, it has not been possible to reproduce these results in the adult. For this reason, a third drug, in this case adriamycin in a low dose, was added to the vincristineprednisone combination in the treatment of adult acute lymphoblastic leukemia (ALL). Complete remission was achieved in 45 of the 50 patients (90%). The median duration of remission was 23 months and the median survival time in this group was 31 months. The complications were minimal and the tolerance was good. From the point of view of our results and others reported in the literature, we consider that the combination of vincristine, prednisone, and adriamycin is a useful method for induction of remission of adult ALL.

📜 SIMILAR VOLUMES

Treatment of acute lymphoblastic leukemi

Treatment of acute lymphoblastic leukemia in adults

✍ Prof. Tiziano Barbui; Renato Bassan; Teodoro Chisesi; Raffaele Battista; Sergio 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 276 KB

Thirty-seven adult patients with acute lymphoblastic leukemia were treated with a protocol called HEAV'D including Adriamycin, Vincristine, L-Asparaginase, Cyclophosphamide and Dexamethasone. The complete remission rate was 70 per cent. The median duration of remission was more than 30 months. Patie

Treatment of childhood acute lymphoblast

Treatment of childhood acute lymphoblastic leukemia with intermediate-dose cytosine arabinoside and adriamycin

✍ Ishii, Eiichi ;Hara, Toshiro ;Ohkubo, Kenshi ;Matsuzaki, Akinobu ;Takeuchi, Taka 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 389 KB

Chemotherapy with cyclophosphamide, vinc

Chemotherapy with cyclophosphamide, vincristine, cytosine arabinoside, and prednisone (COAP) in childhood acute lymphoblastic leukemia (ALL)

✍ Sallan, Stephen E. ;Camitta, Bruce M. ;Chan, David M. ;Traggis, Demitrius ;Jaffe 📂 Article 📅 1977 🏛 John Wiley and Sons 🌐 English ⚖ 290 KB

## Abstract Three groups of children with acute lymphoblastic leukemia (ALL) were treated with intermittent cyclophosphamide, vincristine, cytosine arabinoside, and prednisone (COAP). Group A (no prior relapse) and Group B (prior single‐agent relapse) received COAP after 12 months on another chemot

Vincristine treatment of acute lymphobla

Vincristine treatment of acute lymphoblastic leukemia induces transient autonomic cardioneuropathy

✍ Harri E. Hirvonen; Toivo T. Salmi; Esa Heinonen; Kari J. Antila; Ilkka A. T. Väl 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 444 KB 👁 2 views

Reduced respiratory sinus arrhythmia, measured as heart rate variability, is a reliable indicator of autonomic nervous dysfunction, reflecting a damage in vagal cardiac control. The authors studied the heart rate variability (HRV) of nine children treated for acute lymphoblastic leukemia during the

Relapse in childhood acute lymphoblastic

Relapse in childhood acute lymphoblastic leukemia after elective cessation of initial treatment: Failure of subsequent treatment with cyclophosphamide, cytosine arabinoside, vincristine and prednisone (COAP)

✍ Sallan, Stephen E. ;Hitchcock-Bryan, Suzanne 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 425 KB

## Abstract Although the majority of children with acute lymphoblastic leukemia (ALL) can electively stop treatment after 21/2–5 years of continuous disease‐free remission, 20–25% of those patients relapse after discontinuation of therapy. We treated 15 patients whose disease recurred after stoppin

Combination therapy with methotrexate, v

Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia

✍ Alvaro Aguayo; Jorge Cortes; Deborah Thomas; Sherry Pierce; Michael Keating; Hag 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 2 views

BACKGROUND. L-asparaginase in combination with methotrexate has synergistic antileukemic activity in a schedule-dependent fashion. A new preparation of L-asparaginase, polyethylene-glycol conjugated (PEG)-asparaginase, is a pharmacologically different formulation of L-asparaginase with distinct prop